Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Shares Fell 6.18% in April

By Adria Cimino – May 4, 2020 at 10:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A delay in the regulatory submission of Alzheimer’s drug aducanumab weighed on the shares.

What happened

Biogen (BIIB -2.15%) shares fell 6.18% in April, according to data provided by S&P Global Market Intelligence, as the biotech company said it would submit a key drug to the U.S. Food and Drug Administration later than expected.

A researcher works in a biotech lab.

Image source: Getty Images.

As part of an update in its earnings report, Biogen said it would complete the regulatory filing of its investigational Alzheimer's drug, aducanumab, in the third quarter after meetings with the FDA. The company had originally said it would file for U.S. regulatory approval in early 2020. Also, before the recent earnings call, some analysts thought the next step would be completing the filing and that there wouldn't be a need for further meetings with the regulatory agency.

Prior to the April 22 announcement, Biogen's shares had been following the rest of the market higher. The S&P 500 index rebounded 13% in April after entering a bear market a month earlier.

So what

Aducanumab has pretty much driven Biogen share price over the past year. The stock dropped 34% in a matter of days after Biogen halted the program last March, saying the treatment didn't work. In October the shares rebounded 26% in one trading session after Biogen said a broader study showed just the opposite and decided to submit the drug for regulatory approval. Data from that study showed a wider set of patients who had access to a higher dose of the product. Higher doses reduced clinical decline, the company said.

Why is aducanumab such a significant drug for Biogen? Because there currently isn't an FDA-approved treatment that reduces clinical decline in Alzheimer's disease, which affects 5.8 million Americans. According to Zion Market Research, the global Alzheimer's drug market is expected to generate revenue of $5.7 billion by the end of 2024.

Now what

Biogen has opened a Biologics License Application (BLA) with the FDA and said it is preparing for a pre-BLA meeting this summer. After that step, the company will submit its filing. Any news on progress in the filing may lead share direction in the coming months. And the final approval decision is the major catalyst ahead for this biotech stock.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Stock Quote
Biogen
BIIB
$261.69 (-2.15%) $-5.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.